Merck Historical Income Statement

MRK Stock

USD 101.64 1.48 1.44%

Historical analysis of Merck income statement accounts such as Gross Profit of 46.2 B can show how well Merck Company performed in making a profits. Evaluating Merck income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Merck's future profits or losses.

Cash Flow Balance Sheet Income Statement

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Merck Company latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Merck Company is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

About Merck Income Statement Analysis

Merck Company Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Merck shareholders. The income statement also shows Merck investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Merck Income Statement Chart

At this time, Merck's EBITDA is quite stable compared to the past year. Total Operating Expenses is expected to rise to about 43 B this year, although the value of Cost Of Revenue will most likely fall to about 11.7 B.

Gross Profit Income Before Tax Income Tax Expense Research Development Non Operating Income Net Other

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Merck Company minus its cost of goods sold. It is profit before Merck operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Merck income statement and is an important metric when analyzing Merck Company profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Most accounts from Merck's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Merck Company current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

	2021	2022	2023	2024 (projected)
Gross Profit	35.1B	41.9B	44.0B	46.2B
Total Revenue	48.7B	59.3B	60.1B	32.4B

Gross Profit Total Revenue

Merck income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Selling General Administrative	Minority Interest	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Selling And Marketing Expenses	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.21	0.49	0.15	0.25	-0.13	-0.15	0.24	0.78	0.04	0.28	0.8	0.2	0.28	-0.24	0.95	-0.25	-0.47	0.15	-0.31	0.49	-0.29	0.06	0.5	0.52	-0.49
Interest Expense	0.21		0.75	0.96	0.96	0.32	0.32	0.39	0.68	0.92	0.14	-0.28	0.11	0.2	0.8	0.31	-0.36	-0.21	-0.68	-0.69	-0.62	0.41	-0.15	-0.58	-0.59	0.49
Total Revenue	0.49	0.75		0.77	0.68	0.44	0.43	0.61	0.9	0.55	0.48	0.01	0.48	0.19	0.36	0.48	-0.2	-0.14	-0.51	-0.65	-0.38	0.22	0.05	-0.38	-0.24	0.3
Gross Profit	0.15	0.96	0.77		0.94	0.42	0.41	0.46	0.65	0.91	0.18	-0.35	0.19	0.12	0.8	0.27	-0.22	-0.07	-0.72	-0.69	-0.62	0.38	0.03	-0.63	-0.63	0.49
Other Operating Expenses	0.25	0.96	0.68	0.94		0.19	0.19	0.28	0.64	0.97	0.0	-0.24	-0.03	0.16	0.86	0.37	-0.33	-0.24	-0.63	-0.62	-0.48	0.34	-0.1	-0.49	-0.53	0.38
Operating Income	-0.13	0.32	0.44	0.42	0.19		0.99	0.92	0.31	0.12	0.85	-0.37	0.86	0.35	0.09	-0.13	0.13	0.72	-0.41	0.04	-0.51	0.07	0.42	-0.61	-0.46	0.44
Ebit	-0.15	0.32	0.43	0.41	0.19	0.99		0.93	0.3	0.13	0.85	-0.35	0.86	0.36	0.1	-0.14	0.19	0.72	-0.41	0.05	-0.53	0.06	0.42	-0.62	-0.5	0.48
Ebitda	0.24	0.39	0.61	0.46	0.28	0.92	0.93		0.59	0.14	0.94	-0.04	0.93	0.46	0.01	0.23	0.09	0.52	-0.35	-0.07	-0.33	-0.05	0.43	-0.42	-0.29	0.28
Cost Of Revenue	0.78	0.68	0.9	0.65	0.64	0.31	0.3	0.59		0.45	0.5	0.32	0.46	0.3	0.19	0.76	-0.3	-0.26	-0.31	-0.57	-0.1	-0.01	0.06	-0.1	0.0	0.05
Total Operating Expenses	0.04	0.92	0.55	0.91	0.97	0.12	0.13	0.14	0.45		-0.15	-0.4	-0.17	0.09	0.95	0.19	-0.29	-0.21	-0.64	-0.56	-0.55	0.43	-0.15	-0.55	-0.62	0.45
Income Before Tax	0.28	0.14	0.48	0.18	0.0	0.85	0.85	0.94	0.5	-0.15		0.15	0.97	0.51	-0.29	0.22	0.1	0.51	-0.18	0.09	-0.17	-0.14	0.34	-0.22	-0.08	0.17
Total Other Income Expense Net	0.8	-0.28	0.01	-0.35	-0.24	-0.37	-0.35	-0.04	0.32	-0.4	0.15		0.07	0.28	-0.61	0.75	-0.08	-0.44	0.44	0.05	0.71	-0.39	-0.04	0.82	0.73	-0.69
Net Income	0.2	0.11	0.48	0.19	-0.03	0.86	0.86	0.93	0.46	-0.17	0.97	0.07		0.28	-0.3	0.14	0.22	0.58	-0.16	0.03	-0.23	-0.25	0.44	-0.31	-0.17	0.25
Income Tax Expense	0.28	0.2	0.19	0.12	0.16	0.35	0.36	0.46	0.3	0.09	0.51	0.28	0.28		0.0	0.3	-0.27	-0.01	-0.2	0.24	0.06	0.36	-0.14	0.16	0.16	-0.13
Research Development	-0.24	0.8	0.36	0.8	0.86	0.09	0.1	0.01	0.19	0.95	-0.29	-0.61	-0.3	0.0		-0.09	-0.22	-0.11	-0.64	-0.43	-0.62	0.48	-0.17	-0.63	-0.69	0.53
Selling General Administrative	0.95	0.31	0.48	0.27	0.37	-0.13	-0.14	0.23	0.76	0.19	0.22	0.75	0.14	0.3	-0.09		-0.23	-0.45	0.11	-0.35	0.46	-0.22	0.08	0.44	0.39	-0.47
Minority Interest	-0.25	-0.36	-0.2	-0.22	-0.33	0.13	0.19	0.09	-0.3	-0.29	0.1	-0.08	0.22	-0.27	-0.22	-0.23		0.38	0.3	0.27	0.08	-0.24	0.72	-0.12	-0.2	0.04
Net Income From Continuing Ops	-0.47	-0.21	-0.14	-0.07	-0.24	0.72	0.72	0.52	-0.26	-0.21	0.51	-0.44	0.58	-0.01	-0.11	-0.45	0.38		0.04	0.53	-0.23	-0.27	0.56	-0.43	-0.35	0.28
Non Recurring	0.15	-0.68	-0.51	-0.72	-0.63	-0.41	-0.41	-0.35	-0.31	-0.64	-0.18	0.44	-0.16	-0.2	-0.64	0.11	0.3	0.04		0.53	0.71	-0.44	0.21	0.62	0.57	-0.57
Non Operating Income Net Other	-0.31	-0.69	-0.65	-0.69	-0.62	0.04	0.05	-0.07	-0.57	-0.56	0.09	0.05	0.03	0.24	-0.43	-0.35	0.27	0.53	0.53		0.38	-0.29	0.17	0.3	0.27	-0.27
Selling And Marketing Expenses	0.49	-0.62	-0.38	-0.62	-0.48	-0.51	-0.53	-0.33	-0.1	-0.55	-0.17	0.71	-0.23	0.06	-0.62	0.46	0.08	-0.23	0.71	0.38		-0.47	0.18	0.87	0.83	-0.91
Tax Provision	-0.29	0.41	0.22	0.38	0.34	0.07	0.06	-0.05	-0.01	0.43	-0.14	-0.39	-0.25	0.36	0.48	-0.22	-0.24	-0.27	-0.44	-0.29	-0.47		-0.36	-0.29	-0.26	0.32
Interest Income	0.06	-0.15	0.05	0.03	-0.1	0.42	0.42	0.43	0.06	-0.15	0.34	-0.04	0.44	-0.14	-0.17	0.08	0.72	0.56	0.21	0.17	0.18	-0.36		-0.09	-0.09	-0.17
Net Interest Income	0.5	-0.58	-0.38	-0.63	-0.49	-0.61	-0.62	-0.42	-0.1	-0.55	-0.22	0.82	-0.31	0.16	-0.63	0.44	-0.12	-0.43	0.62	0.3	0.87	-0.29	-0.09		0.92	-0.9
Reconciled Depreciation	0.52	-0.59	-0.24	-0.63	-0.53	-0.46	-0.5	-0.29	0.0	-0.62	-0.08	0.73	-0.17	0.16	-0.69	0.39	-0.2	-0.35	0.57	0.27	0.83	-0.26	-0.09	0.92		-0.84
Extraordinary Items	-0.49	0.49	0.3	0.49	0.38	0.44	0.48	0.28	0.05	0.45	0.17	-0.69	0.25	-0.13	0.53	-0.47	0.04	0.28	-0.57	-0.27	-0.91	0.32	-0.17	-0.9	-0.84

Click cells to compare fundamentals

Merck Account Relationship Matchups

Merck income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	3.7B	3.5B	3.2B	3.9B	3.9B	2.8B
Interest Expense	893M	831M	806M	962M	1.1B	1.2B
Total Revenue	46.8B	41.5B	48.7B	59.3B	60.1B	32.4B
Gross Profit	32.7B	27.9B	35.1B	41.9B	44.0B	46.2B
Other Operating Expenses	34.6B	36.0B	35.5B	41.0B	57.2B	60.0B
Operating Income	9.2B	6.1B	13.7B	19.4B	3.0B	5.6B
Ebit	9.2B	6.7B	14.7B	17.4B	3.0B	5.6B
Ebitda	12.9B	10.2B	17.9B	21.3B	6.9B	8.4B
Cost Of Revenue	14.1B	13.6B	13.6B	17.4B	16.1B	11.7B
Total Operating Expenses	20.5B	22.4B	21.9B	23.6B	40.9B	43.0B
Income Before Tax	11.5B	8.8B	13.9B	16.4B	1.9B	1.8B
Total Other Income Expense Net	2.2B	315M	680M	(1.8B)	(1.1B)	(1.0B)
Net Income	9.8B	7.1B	13.0B	14.5B	365M	346.8M
Income Tax Expense	1.7B	1.7B	1.5B	1.9B	1.5B	2.0B
Research Development	9.9B	13.4B	12.2B	13.5B	30.5B	32.1B
Selling General Administrative	8.7B	7.2B	7.6B	7.8B	8.2B	8.7B
Net Income Applicable To Common Shares	9.8B	7.1B	13.0B	14.5B	16.7B	17.5B
Minority Interest	(66M)	15M	691M	(7M)	(13M)	(12.4M)
Net Income From Continuing Ops	9.8B	7.1B	12.4B	14.5B	4.6B	8.0B
Non Recurring	638M	578M	661M	337M	303.3M	288.1M
Non Operating Income Net Other	(139M)	886M	1.3B	(1.5B)	(1.4B)	(1.3B)
Selling And Marketing Expenses	1.9B	1.8B	2B	2.2B	2.3B	2.2B
Tax Provision	1.7B	1.7B	1.5B	1.9B	2.8B	2.2B
Interest Income	274M	59M	1.9B	1.3B	390M	732.6M
Net Interest Income	(619M)	(772M)	(770M)	(805M)	(681M)	(715.1M)
Reconciled Depreciation	3.7B	3.6B	3.2B	3.9B	3.8B	3.1B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:

How To Invest In Merck

Details

Is Merck Stock a good investment?

Details

What is Merck's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.33)

Dividend Share

3.04

Earnings Share

4.78

Revenue Per Share

24.931

Quarterly Revenue Growth

0.044

The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Merck Historical Income Statement

About Merck Income Statement Analysis

Merck Income Statement Chart

Gross Profit

Income Before Tax

Merck income statement Correlations

Merck Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Merck income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebit	+ 0.99	Operating Income
Total Operating Expenses	+ 0.97	Other Operating Expenses
Net Income	+ 0.97	Income Before Tax
Gross Profit	+ 0.96	Interest Expense
Other Operating Expenses	+ 0.96	Interest Expense
Selling General Administrative	+ 0.95	Depreciation And Amortization

Extraordinary Items	- 0.91	Selling And Marketing Expenses
Extraordinary Items	- 0.9	Net Interest Income
Extraordinary Items	- 0.84	Reconciled Depreciation
Non Recurring	- 0.72	Gross Profit
Reconciled Depreciation	- 0.69	Research Development
Extraordinary Items	- 0.69	Total Other Income Expense Net